AHUSAtypical Hemolytic Uremic Syndrome
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
The Phase 3 study of ULTOMIRIS, administered intravenously every eight weeks in adult patients with aHUS, met its primary objective.
Ultomiris is also currently being evaluated in a Phase 3 clinical study in children and adolescents with aHUS, administered intravenously every eight weeks.
This is a devastating disease which has a limited clinical understanding and treatment options.8 Classically pregnancy associated aHUS occurs in post partum period, the overall prevalence reported is 26%, with 71% presenting during the first pregnancy.9 Long term renal prognosis in pregnancy associated aHUS has been reported poor.8,9 Even the response to plasma exchange has also been reported poor in pregnancy related HUS.8 To best of our knowledge based on literature search no case has been reported with Kikuchi disease along with Hemolytic uremic syndrome and renal failure.
The company believes that the dual action of Coversin on both C5 and LTB4 may be beneficial in AKC, BP, and aHUS.
The air handling unit (AHU) segment is expected to grow at the fastest rate between 2018 and 2023, stated the report.
Based on Table 6.5.1-1, all AHUs in this building require air economizers.
Hamza was diagonsed with aHUS in October 2016 and has since been on life-saving medicine which costs Dh27,980 per dose besides an additional Dh2,000 for lab tests and hospital care.
However, specific complement gene pathway mutations are found in only 50-60% of cases of true aHUS [8].
In the differential diagnosis of thrombotic microangiopathy, HUS was eliminated due to the absence of Shiga toxin-induced infection and bloody diarrhea; disseminated intravascular coagulation (DIC) was excluded based on normal PT, aPTT, and fibrinogen levels; and thrombotic thrombocytopenic purpura (TTP) was excluded due to the negative ADAMTS13 test; based on the laboratory and clinical findings, the patient was diagnosed with aHUS. Eculizumab, which is a humanized monoclonal antibody that blocks complement activity by cleavage of the complement protein C5, was added to the hemodialysis and plasmapheresis treatment.
It is estimated that aHUS affects around 200 people in the UK, with 20 to 30 new diagnoses each year.
Before Eculizumab the prognosis for those diagnosed with aHUS was poor.